CD274 and non-small cell lung carcinoma: There is no uniform conclusion about its economic impact at present (10, 11), and the systematic review showed that checkpoint inhibitors as a first-line treatment for NSCLC has no economic advantage versus conventional chemotherapy regardless of PD-L1 level (12).